Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Silicon containing doai
C514S217040, C514S235500, C514S253010, C514S278000, C514S295000, C514S309000, C514S318000, C514S326000, C514S331000, C514S336000, C514S339000, C514S343000, C514S357000, C514S376000, C514S600000, C540S597000, C544S131000, C544S360000, C546S014000, C546S017000, C546S097000, C546S141000, C546S194000, C546S209000, C546S232000, C546S276700, C546S279100, C546S283400, C546S334000, C548S229000, C564S079000
Sulfamide compounds having formula (I) are described as well as their use in the treatment of diseases dependent on the signaling pathways associated with β-adrenergic receptors, such as obesity, diabetes, hypertension, gastrointestinal hypo- or hyper-motility and cardiovascular diseases
patent: 4358455 (1982-11-01), Atkinson et al.
patent: 4478849 (1984-10-01), Ainsworth et al.
patent: 5019578 (1991-05-01), Fisher et al.
patent: 5030640 (1991-07-01), Fisher et al.
patent: 5153210 (1992-10-01), Ainsworth et al.
patent: 5705515 (1998-01-01), Fisher et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5792871 (1998-08-01), Chartrain et al.
patent: 5977124 (1999-11-01), Dow
patent: 0516349 (1992-12-01), None
patent: WO9529159 (1995-02-01), None
patent: WO9804526 (1998-02-01), None
patent: WO9965877 (1999-12-01), None
patent: WO0206274 (2002-01-01), None
Tesfamariam, B. et al., “β1—and β2-Adrenoceptor Antagonist Activities of ICI-215001, a Putative β3-Adrenoceptor Agonist”, 1 55-58 (1994).
Martin, et al., “Effects of Two β3-Adrenoceptor Agonists, SR 58611A and BRL 37344, and of Salbutamol on Cholinergic and NAN Neural Contraction in Guinea-pig Main Bronchi in vitro”, 110, 1311-1316 (1993).
Giudice, et al., “Inhibition of Rat Colonic Motility and Cardiovascular Effects of New Gut-Specific Beta-Adrenergic Phenylethanolaminotetralines”, 44, 1411-1417(1989).
Simland, et al., “Antidepressant Profile in Rodents of SR 58611A, a New Selective Agonist for Atypical β-adrenoceptors”, 219, 19 201(1992).
Taneja, et al., “Evidence for a Noradrenergic innervation to “Atypical” Beta Adrenoceptors (or Putative Beta-3 Adrenoceptors) the lieum of Guinea Pig”, 260, 192-200 (1992).
Krief, et al., “Tissue Distribution of β3-adrenergic Receptor mRNA in Man”, 91 344-349 (1993).
Dow Robert L.
Paight Ernest S.
Benson Gregg C.
Musser Arlene K.
Richardson Peter C.
β3 agonists and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.If you have personal experience with β3 agonists and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and β3 agonists and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3449895